Brief: Cellares, Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201
06/11/2023 13:20
Nov 6 (Reuters) - Cabaletta Bio Inc CABA.O :
* CELLARES AND CABALETTA BIO PARTNER TO EVALUATE AUTOMATED
MANUFACTURING FOR CABA-201, CABALETTA’S CD19-CAR T CELL THERAPY
ON CELLARES’ CELL SHUTTLE PLATFORM
* CABALETTA BIO INC: COLLABORATION WITH INTENT TO VALIDATE
CELLARES' CELL SHUTTLE PLATFORM FOR MANUFACTURING OF CABA-201
Source text for Eikon: ID:nBw5nScLba
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsBrief: Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cabaletta Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cabaletta Bio Q2 net loss widens as R&D costs rise
Cabaletta Bio, Inc. expected to post a loss of 37 cents a share - Earnings Preview
Cabaletta Bio Inc expected to post a loss of 37 cents a share - Earnings Preview